What is he best known for?
The fields of study he is best known for:
- Antibody
- Immune system
- Gene
His scientific interests lie mostly in Antibody, Monoclonal antibody, Virology, Immunology and Epitope.
His Antibody study incorporates themes from Molecular biology, Antigen and In vivo.
Paul W. H. I. Parren has researched Monoclonal antibody in several fields, including Ebolavirus and Cytotoxicity.
His Virology study integrates concerns from other disciplines, such as Peptide library and Phage display.
His Immunology research focuses on Cancer research and how it connects with Immunotherapy, Growth factor receptor, Mechanism of action and Ex vivo.
His Epitope research includes elements of Viral envelope, Glycoprotein and Complementarity determining region.
His most cited work include:
- Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody (1075 citations)
- Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. (759 citations)
- Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. (756 citations)
What are the main themes of his work throughout his whole career to date?
Paul W. H. I. Parren mostly deals with Antibody, Immunology, Monoclonal antibody, Molecular biology and Virology.
His studies deal with areas such as Cancer research, Antigen and Cytotoxicity as well as Antibody.
Paul W. H. I. Parren conducts interdisciplinary study in the fields of Monoclonal antibody and Diagnostic methods through his works.
His biological study spans a wide range of topics, including Cell culture, T cell, Biochemistry, Complement-dependent cytotoxicity and Primary and secondary antibodies.
In his work, Immunoglobulin G is strongly intertwined with Cell biology, which is a subfield of Complement system.
He has researched Epitope in several fields, including Viral envelope and Binding site.
He most often published in these fields:
- Antibody (73.17%)
- Immunology (37.56%)
- Monoclonal antibody (35.61%)
What were the highlights of his more recent work (between 2016-2021)?
- Antibody (73.17%)
- Cancer research (26.34%)
- Cytotoxicity (19.76%)
In recent papers he was focusing on the following fields of study:
Paul W. H. I. Parren spends much of his time researching Antibody, Cancer research, Cytotoxicity, Immunology and Monoclonal antibody.
His Antibody research is multidisciplinary, incorporating elements of Cell, Molecular biology and Antigen.
His Molecular biology study incorporates themes from Cell biology, Complement system and Cancer immunotherapy.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Cancer, Immunotherapy, In vitro and In vivo.
His work carried out in the field of Immunology brings together such families of science as Computational biology, Rodent and Neoplasms therapy.
In his research, Degranulation is intimately related to Chronic lymphocytic leukemia, which falls under the overarching field of Monoclonal antibody.
Between 2016 and 2021, his most popular works were:
- Bispecific antibodies: a mechanistic review of the pipeline. (215 citations)
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. (90 citations)
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. (90 citations)
In his most recent research, the most cited papers focused on:
- Antibody
- Gene
- Immune system
His primary areas of study are Cancer research, Antibody, Immunology, Immunotherapy and Daratumumab.
The various areas that Paul W. H. I. Parren examines in his Cancer research study include Receptor tyrosine kinase, In vivo and Cytotoxicity.
In the subject of general Antibody, his work in Immunoglobulin G is often linked to Proteases, thereby combining diverse domains of study.
His studies in Immunotherapy integrate themes in fields like Relapsed refractory, Multiple myeloma and Fc-Gamma Receptor.
His Daratumumab research incorporates elements of Tumor microenvironment, Antibody-dependent cell-mediated cytotoxicity, Peripheral blood mononuclear cell, CD38 and Leukemia.
His Monoclonal antibody research is multidisciplinary, incorporating perspectives in Cancer cell, Cell culture and Antigen, CD20.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
